Ovid Therapeutics (OVID) vs Prothena (PRTA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Ovid Therapeutics (OVID) has outperformed Prothena (PRTA) over the past year, gaining 41.3% versus a loss of 16.6%. Over five years, OVID leads with a -34.4% price change compared with -86.6% for PRTA. Ovid Therapeutics is the larger company by market cap ($454.1 million vs $441.5 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | OVID | PRTA |
|---|---|---|
| Share price | $2.33 | $8.60 |
| Market cap | $454.07M | $441.50M |
| 1-day change | -1.48% | +1.41% |
| YTD return | +44.79% | -11.20% |
| 1-year return | +41.32% | -16.62% |
| 5-year return | -34.44% | -86.64% |
| EPS (TTM) | $-0.22 | $-0.82 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $3.11 | $11.80 |
| 52-week low | $1.18 | $7.73 |
| Distance from 52-week high | -25.12% | -27.12% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +158.92% | +148.84% |
| Average volume | 1.58M | 482.01K |
| Shares outstanding | 195.30M | 51.34M |
| Employees | 23 | 67 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- OVID has outperformed PRTA by 57.9 percentage points over the past year.
About Ovid Therapeutics
OVID stock →Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of small molecule medicines for brain disorders including epilepsies and seizure-related neurological disorders in the United States. The company is developing OV329, a GABA-AT inhibitor which is in Phase 1 clinical trials for the treatment of adult and infant drug-resistant epilepsies; and OV4071, a first-in-human oral potassium-chloride cotransporter 2 direct activator which is in Phase 1 clinical trials for the treatment of psychosis associated with parkinson's disease, lewy body dementia, and acute schizophrenia.
Health Care · Biotechnology: Pharmaceutical Preparations · 23 employees
About Prothena
PRTA stock →Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation. Its product pipeline includes Prasinezumab, an investigational humanized monoclonal antibody which is in Phase 3 clinical trial for the treatment of parkinson's disease and other synucleinopathies.
Health Care · Biotechnology: Pharmaceutical Preparations · 67 employees
OVID vs PRTA FAQ
Which is bigger, Ovid Therapeutics or Prothena?
Ovid Therapeutics (OVID) is larger, with a market capitalization of $454.07M compared with $441.50M for Prothena (PRTA).
Which stock has performed better over the past year, OVID or PRTA?
OVID returned +41.32% over the past 12 months, compared with -16.62% for PRTA (price return, excluding dividends). Past performance does not predict future results.
Are Ovid Therapeutics and Prothena in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.